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Abstract
Background: The aim was to analyse trends in clinically relevant resistance to first-line antiretroviral drugs in Spain, applying
the Stanford algorithm, and to compare these results with reported Transmitted Drug Resistance (TDR) defined by the 2009
update of the WHO SDRM list.
Methods: We analysed 2781 sequences from ARV naive patients of the CoRIS cohort (Spain) between 2007–2011. Using the
Stanford algorithm ‘‘Low-level resistance’’, ‘‘Intermediate resistance’’ and ‘‘High-level resistance’’ categories were considered
as ‘‘Resistant’’.
Results: 70% of the TDR found using the WHO list were relevant for first-line treatment according to the Stanford algorithm.
A total of 188 patients showed clinically relevant resistance to first-line ARVs [6.8% (95%Confidence Interval: 5.8–7.7)], and
221 harbored TDR using the WHO list [7.9% (6.9–9.0)]. Differences were due to a lower prevalence in clinically relevant
resistance for NRTIs [2.3% (1.8–2.9) vs. 3.6% (2.9–4.3) by the WHO list] and PIs [0.8% (0.4–1.1) vs. 1.7% (1.2–2.2)], while it was
higher for NNRTIs [4.6% (3.8–5.3) vs. 3.7% (3.0–4.7)]. While TDR remained stable throughout the study period, clinically
relevant resistance to first line drugs showed a significant trend to a decline (p = 0.02).
Conclusions: Prevalence of clinically relevant resistance to first line ARVs in Spain is decreasing, and lower than the one
expected looking at TDR using the WHO list. Resistance to first-line PIs falls below 1%, so the recommendation of screening
for TDR in the protease gene should be questioned in our setting. Cost-effectiveness studies need to be carried out to
inform evidence-based recommendations.
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Introduction
HIV drug resistance due to transmitted mutations in the reverse
transcriptase (RT) and protease (Pro) regions has been associated
with a higher risk of virological failure to first line antiretroviral
therapy (ART) [1], having a greater impact for initial regimens
containing a non-nucleoside reverse transcriptase inhibitor
(NNRTI) [2]. Testing for transmitted drug resistance (TDR) in
newly diagnosed patients with HIV is strongly recommended by
treatment guidelines [3–6], as it has shown to be cost-effective, in
terms of gain in quality-adjusted life year (QALYs) when drug
resistance prevalence is over 1–5% [7].
The Spanish cohort of naı¨ve HIV infected individuals (CoRIS)
offers relevant information about the current epidemiological
profile of HIV infection [8,9], and is an excellent scenario to
characterise the prevalence of TDR over time in Spain. Two
previous analyses of viral sequences in CoRIS were carried out for
the periods 2004–2008 and 2007–2010, and have been published
elsewhere [10,11]. For these two previous studies, we used the
2009 update World Health Organization (WHO) comprehensive
list of mutations [12], which has been also widely used for TDR
evaluation [13–16]
WHO mutations list has overcome the major limitation of TDR
studies across the world, thus providing high levels of standard-
ization into these studies. However, it defines TDR to the different
classes of antiretroviral drugs based on the presence of at least one
mutation related to drug resistance, while first line treatment drugs
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that are currently approved by many of the latest updates of
clinical guidelines, often include compounds, for which more than
one mutation is necessary in order to reduce in vivo drug activity
(e.g, abacavir, and boosted Protease Inhibitors). Further approach-
es, such as the Stanford HIV Drug Resistance Database algorithm,
calculate the effective resistance given the combination of
mutations present in a particular strain, allowing analyzing
clinically relevant resistance to specific antiretroviral drugs (ARVs)
and regimens, providing a complementary and invaluable input
for informing clinical recommendations.
The objective of this study was to analyse clinically relevant
resistance to drugs included in recommended first-line regimens in
Spain (CoRIS) from 2007 to 2011, using the Stanford algorithm,
and compare it to TDR, defined by the WHO list of mutations.
Patients and Methods
CoRIS is an open, multicentre, prospective cohort of HIV-
positive, antiretroviral-naı¨ve subjects over 13 years of age,
including both seroprevalent and seroconverter patients. Subjects
are recruited and followed up in 31 HIV units from 13 of the 17
Autonomous Communities of Spain. Ethics approval was obtained
from participating sites and a written informed consent was
obtained from every patient included in the study. Detailed
descriptions of the cohort have been previously published [8,9]. As
part of the cohort data collection process, which began in 2004,
sites are asked every year to provide a FASTA viral sequence,
encoding the HIV protease and RT obtained at the time of
inclusion, available from routine resistance testing. As of October
2011, 23 sites from 10 Autonomous Communities were collabo-
rating in the collection of FASTA sequences. In the cohort-
coordinating centre, these sequences are linked to clinical and
epidemiological data of the patient. Further, the cohort coordi-
nating centre double checks that dates of FASTA sample
collection are previous to initiation of ART. Study period for this
analysis was from January 2007 to October 2011 and only naı¨ve
patients with availability of a FASTA sequence of medium or high
quality were included. Sequence data may be available to qualified
researchers upon request.
Clinically relevant drug resistance to the first line antiretrovirals
(ARVs) included in recommended first-line regimens in Spain as of
current guidelines [6] [abacavir, emtricitabine, lamivudine and
tenofovir, (Nucleoside Analogue Reverse Transcriptase Inhibitors,
NRTIs), efavirenz and nevirapine (Non-Nucleoside Analogue
Reverse Transcriptase Inhibitors, NNRTIs), atazanavir, darunavir
and lopinavir (Protease Inhibitors, PIs)] was evaluated using the
Stanford Database algorithm [17]. For analysis, Stanford HIVdb
‘‘Low-level resistance’’, ‘‘Intermediate resistance’’ and ‘‘High-level
resistance’’ categories were considered as ‘‘Resistant’’, while
‘‘Susceptible’’ and ‘‘Potential Low Level Resistance’’ were pooled
into Susceptible. For subsequent genotypic sensitivity score (GSS)
analysis, ‘‘Susceptible’’ and ‘‘Potential Low Level Resistance’’
were scored as 1, ‘‘Low Level Resistance’’ and ‘‘Intermediate
Resistance’’ were pooled into Intermediate and scored as 0.5, and
‘‘High Level Resistance’’ was scored as 0. GSS was calculated
adding individual resistance scores for each first-line drug in the
regimen.
Alternatively, transmitted drug resistance (TDR) associated
mutations were evaluated following the WHO surveillance drug
resistance mutation list updated in 2009 by Bennett and colleagues
[12].
The sample was described using proportion or median
(interquartile range) for categorical and continuous variables,
respectively; and bivariate analysis was performed using Chi
Square or Kruskall-Wallis test as appropriate. Resistance muta-
tions were described using prevalence, and the corresponding
confidence intervals were calculated with an analytically derived
variance estimator. Their linear trend over the study period was
analysed using chi-square test for trend. Significance level was 5%.
All the analyses were conducted using Stata software (V.11.1,
Stata Corporation, College Station, Texas, USA).
Results
A total of 23 out of the 28 centres in CoRIS contributed FASTA
sequences from 2007 to 2011. These centres provided 7,351
patients, 92.2% of the CoRIS cohort, and a complete naı¨ve
sequence was submitted for 2,781 (37.8%). Compared to the total
cohort, those with an available FASTA sequence were younger
(median age 33.9 vs. 34.9), more frequently males (88.3% vs.
83.9%), infected through sex between men (69.2% vs. 58.9%),
with a higher educational level (63.5% vs. 56.2%), originating
from Spain compared to other regions (70.1% vs. 68.0%), and
recruited in earlier stages of HIV disease progression (CD4 count
at recruitment 424 vs. 323 cells/mm3). All differences were
statistically significant at p,0.01.
A description of the study population by year in which sample
for sequencing was obtained is shown in Table 1. An increase in
the proportion of men who have sex with men (MSM), of subjects
with a higher education, and of patients at earlier CDC stages and
higher CD4 counts was observed over time. Median time from
cohort entry to resistance study was -1 day (IQR: -21 to 13).
Transmitted Drug Resistance (TDR) according to the
WHO list
A total of 221 patients had at least one mutation among those
contained in the WHO surveillance list, giving a prevalence of
TDR of 7.9% (95%Confidence Interval: 6.9–9.0). Regarding
mutations affecting specific ARV classes, similar prevalence of
TDR was found for nucleoside reverse transcriptase inhibitors
(NRTIs) and non-NRTIs (NNRTIs), being 3.6% (2.9–4.3) for
NRTIs and 3.7% (3.0–4.7) for NNRTIs. TDR to protease
inhibitors (PIs) was less prevalent, of 1.7% (1.2–2.2). Figure 1
shows prevalence of TDR for each ARV class throughout the
study period. TDR to NNRTIs decreased from 5.2% in 2007 to
2.8% in 2011, although the trend was not statistically significant.
TDR to more than one class of ARV was uncommon; 1.0% (0.6–
1.3) and 0.1% (0.0–0.2) of the subjects showed TDR to a
minimum of two or three ARV classes, respectively. TDR to two
ARV classes decreased from 1.5% in 2007 to 0.3% in 2011, but
again was not statistically significant.
Table 2 shows prevalence of specific mutations in the WHO
surveillance list. The main mutation related to TDR to NNRTI
was K103N/S, which had a prevalence of 2.8% (2.2–3.4). Three
mutations were identified as being mainly responsible for TDR to
NRTIs: T215 revertants (C/D/E/N/I/V/S) (1.3%; 0.9–1.8),
M41L (1.2%; 0.8–1.5) and K219EQNR (1.0%; 0.7–1.4). For PIs,
the mutation mainly responsible for TDR was M46IL (0.9%; 0.6–
1.3). Of interest, a single mutation (singleton) was responsible for
TDR to NRTIs, NNRTIs or PIs in 55.5%, 85.3% and 93.8% of
the cases.
Clinically relevant resistance to first-line drugs according
to the Stanford Algorithm
When investigating clinically relevant resistance to ARV drugs
that make part of recommended initial regimens, the number of
patients that showed any resistance was 188, for a total prevalence
of 6.8% (5.8–7.7). Prevalence of clinically relevant resistance to
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any first line ARV was lower than TDR for NRTIs [2.3% (1.8–
2.9)] and PIs [0.8% (0.4–1.1)], while it increased in the case of
NNRTIs to reach 4.6% (3.8–5.3). In fact, only 70.1% of patients
harboring TDR actually showed any clinically relevant resistance
to first-line drugs. Percentages for NRTIs and PIs were 65.3% and
35.4%, respectively. For NRTIs, the mutations responsible for
having TDR, but without clinically relevant resistance to first line
drugs, were present mainly as singletons: a Thymidine Associated
Mutation (TAM) alone (M41L, n = 8; T69D, n = 1; K70R, n = 1;
L210W, n = 4; K219N/Q, n = 7), a T215 revertant alone (D/N/S
n = 7), a F77L alone (n = 2), or a combination of D67N+K219Q
(n = 4), or D67N+T69D (n = 1). For PIs, mutations responsible for
these discordances were always detected as singletons (L24I, n = 1;
D30N, n = 1; M46I/L, n = 24; F53Y, n = 1, V82L, n = 2 and
N88D, n = 2). On the other hand, the increase in clinically
relevant resistance for NNRTIs was driven mainly by the
combination of two or more mutations that are not present in
the WHO list (V90I+V108I+H221Y, n = 1; A98G+V179E, n = 1;
V108I+E138A, n = 3; V108I+V179E, n = 2; E138A+V179D,
n = 2; E138A+V179D+Y188H, n = 1; V179D+ V106I, n = 1),
and in 7 cases by the presence of a A98G singleton.
Figure 2 shows the prevalence of clinically relevant resistance to
first line ARV drugs by ARV class. A significant decrease
(p = 0.02) was found from 2007 (8.1%) to 2011 (4.7%), explained
by a borderline statistical significance decrease in both NRTIs and
NNRTI. No trend was found in case of PIs. Primary drug
resistance to two or three ARV classes was low, of 0.8% (0.5–1.2)
and of 0.04% (0.0–0.1), respectively.
For individual first line NRTIs, clinically relevant resistance was
2.2% (1.7–2.8) for abacavir, 0.7% (0.4–1.0) for emtricitabine and
lamivudine, and 1.6% (1.1–2.1) for tenofovir; for first line
NNRTIs, resistance was observed in 4.0% (3.3–4.8) for efavirenz
and 4.6% (3.8–5.3) for nevirapine; finally, for PIs, resistance was
Table 1. Baseline characteristics of the study population.
2007 2008 2009 2010 2011 Total
(N = 484) (N = 582) (N = 596) (N = 756) (N = 363) (N = 2,781) p
n (%) n % n % n % n % n %
Sex (Male) 436 90.1 481 82.6 529 88.8 683 90.3 326 89.8 2,455 88.3 ,0.01
Age*, Median (IQR) 33.8 (28.3–41.0) 34.3(28.2–41.5) 33.2(28.0–39.7) 34.5(28.5–41.6) 33.8(27.3–42.3) 33.9 (28.2–41.0) 0.37
Mode of
transmission
IDU 35 7.2 47 8.1 27 4.5 38 5.0 14 3.9 161 5.8
MSM 321 66.3 347 59.6 429 72.0 550 72.8 278 76.6 1,925 69.2 ,0.01
Heterosexual 119 24.6 178 30.6 126 21.1 140 18.5 63 17.4 626 22.5
Other/NA 9 1.9 10 1. 7 14 2.4 28 3.7 8 2.2 69 2.5
Country of origin Spain 331 68.4 408 70.1 435 73.0 513 67.9 262 72.2 1,949 70.1
Africa 22 4.5 23 4.0 27 4.5 23 3.0 7 1.9 102 3.7 0.07
Latin America 106 21.9 108 18.6 106 17.8 174 23.0 67 18.5 561 20.2
Other/unknown 25 5.2 43 7.4 28 4.7 46 6.1 27 7.4 169 6.1
Educational level Lower 127 26.2 175 30.1 148 24.8 191 25.3 88 24.2 729 26.2
Higher 299 61.8 341 58.6 380 63.7 503 66.5 244 67.2 1,767 63.5 ,0.05
Unknown 58 12.0 66 11.3 68 11.4 62 8.2 31 8.5 285 10.3
Viral Load* (log c/
ml)
N 349 429 440 622 291 2,131 0.11
Median (IQR) 4.5 (4.0–5.1) 4.6 (4.0–5.0) 4.6 (4.0–5.1) 4.6 (4.1–5.1) 4.7 (4.2–5.2) 4.6 (4.1–5.1)
CD4 count * (cells/
mm3)
N 416 501 503 699 330 2,449 ,0.05
Median (IQR) 392 (237–604) 371 (223– 559) 396 (251– 593 413 (276–580) 432(260–606) 399 (251–588)
Duration of the
infection*
Recent infection 43 8.9 47 8.1 51 8.6 70 9.3 34 9.4 245 8.8
Chronic infecion 112 23.1 121 20.8 138 23.1 169 22.3 76 20.9 616 22.2 0.96
Not evaluable 329 68.0 414 71.1 407 68.3 517 68.4 253 69.7 1,920 69.0
CDC stage* P/A 402 83.6 492 84.8 537 90.2 658 87.2 326 89.8 2,415 87.1
B 40 8.3 38 6.6 29 4.9 53 7.0 23 6.3 183 6.6 ,0.05
C 39 8.1 50 8.6 29 4.9 44 5.8 14 3.9 176 6.3
History of delayed
diagnosis
Yes 149 30.8 205 35.2 169 28.4 218 28.8 114 31.4 855 30.7
No 248 51.2 277 47.6 325 54.5 439 58.1 192 53.0 1,481 53.3 ,0.05
Not evaluable 87 18.0 100 17.2 102 17.1 99 13.1 57 15.7 445 16.0
*At the time of the resistance testing; IDU: injecting drug users; MSM: men who have sex with men; P/A: Primoinfection or CDC stage A; NA: Not available; IQR:
interquartile range.
doi:10.1371/journal.pone.0090710.t001
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observed in 0.7% (0.4–1.0) for atazanavir, 0.1% (0.0–0.3) for
darunavir, and 0.3% (0.1–0.5) for lopinavir.
Therapeutic barrier to resistance of first-line drug
regimens
Table 3 shows resistance when combining these drugs into first
line recommended regimens. Overall, 188 patients (6.8%) showed
resistance to at least one regimen (GSS #3). Most affected
regimens were those containing NNRTIs with patients showing
resistance between 5.6% and 6.2%, depending on the specific
combination of drugs. Resistance to PI based regimens was less
common, between 2.2% and 2.7%. Of note, only 0.7% to 0.9% of
the PI containing regimens showed two or less fully active drugs.
Figure 1. Prevalence of TDR (WHO SDRM estimates) by antiretroviral class between 2007 and 2011. NRTI: nucleoside reverse
transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors. * p value for Chi-square test for trend.
doi:10.1371/journal.pone.0090710.g001
Table 2. Prevalence of mutations from the WHO transmitted drug resistance surveillance list.
NRTI mutations NNRTI mutations PI mutations
Mutation N (Pv, %) Mutation n (Pv, %) Mutation n (Pv, %)
M41L 32 (1.15) L100I 2 (0.07) L24I 2 (0.07)
K65R 1 (0.04) K101EP 8 (0.29) D30N 1 (0.04)
D67EGN 23 (0.83) K103N/S 77 (2.77) V32I 2 (0.07)
T69D 5 (0.18) Y181CIV 9 (0.32) M46IL 26 (0.93)
K70ER 5 (0.18) Y188CHL 5 (0.18) I47AV 2 (0.07)
L74IV 3 (0.11) G190AES 11 (0.40) F53LY 2 (0.07)
F77L 2 (0.07) P225H 3 (0.11) I54ALMSTV 2 (0.07)
Y115F 2 (0.07) M230L 1 (0.04) V82ACFLMST 5 (0.18)
M184IV 13 (0.47) N83D 1 (0.04)
L210W 12 (0.43) I85V 1 (0.04)
T215REV* 37 (1.33) N88DS 2 (0.07)
T215YF 2 (0.07) L90M 10 (0.36)
K219EQNR 29 (1.04)
1 mut. 56 (2.01) 1 mut. 87 (3.13) 1 mut. 45 (1.62)
2 mut. 32 (1.15) 2 mut. 13 (0.47) 2 mut. 2 (0.07)
$3 mut. 13 (0.47) $3 mut. 2 (0.07) $3 mut. 1 (0.04)
Prevalence (95%CI) 3.6 (2.9–4.3) Prevalence (95%CI) 3.7 (3.0–4.4) Prevalence (95%CI) 1.7 (1.2–2.2)
NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitors; Pv: prevalence; mut.:mutation. Amino
acide abbreviations: A, alanine; C, cysteine; D, aspartate; E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M methionine; N,
asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine. * = C/D/E/N/I/V/S.
doi:10.1371/journal.pone.0090710.t002
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Discussion
Our study shows that, in Spain for the period 2007–2011, the
prevalence of clinically relevant resistance to approved first line
ARV drugs analyzed using the Stanford HIV interpretation
system is lower than the one we would expect when looking at the
Transmitted Drug Resistance (TDR) defined in the WHO
mutations list. Moreover, a significant trend to a reduction in
resistance was found, driven by a decrease in resistance to the first
line NNRTIs efavirenz and nevirapine, as well as to the NRTIs
abacavir, emtricitabine, lamivudine, and tenofovir, while resis-
tance to the PIs atazanavir, darunavir and lopinavir, remained
stable and very low throughout the whole period. In contrast, no
significant trend in the TDR defined by WHO list has been
observed. Resistance to more than one antiretroviral class was very
uncommon by year 2011.
Many studies have evaluated trends in TDR transmission across
Europe and the US [10,11,13–16,18–21]. The use of the 2009
update of the WHO surveillance recommendations for the
estimation of TDR has brought uniformity to all TDR surveys,
and has had the great benefit of making all these studies
comparable. It also has proved extremely useful for characterizing
the epidemiology of TDR and carrying out population-based
surveillance. However, its correlation with resistance to the
different ARVs is not always straightforward, and further analysis
of these mutations such as the one proposed by the Stanford HIV
Resistance Database, can provide a complementary and useful
input to clinicians, public health professionals and policy makers to
develop evidence-based clinical guidelines.
In our study, TDR was of 7.9%, higher than clinically relevant
resistance to first line drugs (prevalence of 6.8%). This shows that
effective resistance to first line regimens in Spain would lie below
the one we would expect when looking at the list of resistance
mutations surveillance. In fact, up to 30% of patients harboring
TDR did not actually show clinically relevant resistance, being this
percentage higher in the case of PIs (65%) and NRTIs (34%).
Specifically looking at clinical resistance to first line drugs is
therefore relevant and can have important implications.
Clinically relevant resistance to first line PIs remained below 1%
for all years except 2007, and was mostly of intermediate level,
showing that transmitted resistance to PIs is not threatening
effectiveness of PI-based first line ART in Spain. In agreement
with what was previously suggested by an Irish report [14], our
study greatly supports the hypothesis that there is no need from the
clinical point of view to screen for PI resistance in our setting,
though having the protease sequence may be useful for
epidemiologic studies tracing TDR. A recent study has reported
a misinterpretation of resistance to PIs, with an increase in the
level of transmitted resistance to this class of antiretrovirals when
using the WHO list [22]. In our study we have found that focusing
Figure 2. Prevalence of clinically relevant resistance to first line drugs (Stanford HIVdb) by antiretroviral class between 2007 and
2011. NRTI: nucleoside reverse transcriptase inhibitors (abacavir, emtricitabine, lamivudine and tenofovir); NNRTI: non-nucleoside reverse
transcriptase inhibitors (efavirenz and nevirapine); PI: protease inhibitors (atazanavir, darunavir and lopinavir). * p value for Chi-square test for trend.
doi:10.1371/journal.pone.0090710.g002
Table 3. Therapeutic barrier of first line ARV regimens using
Stanford Algorithm.
ARV regimen Genotypic Sensitivity Score
,3 #2
n (%) n (%)
EFV TDF FTC/3TC 155 (5.6) 94 (3.4)
ABC FTC/3TC 157 (5.7) 95 (3.4)
NVP TDF FTC/3TC 169 (6.1) 109 (3.9)
ABC FTC/3TC 171 (6.2) 109 (3.9)
LPV TDF FTC/3TC 64 (2.3) 20 (0.7)
ABC FTC/3TC 68 (2.5) 20 (0.7)
ATZ TDF FTC/3TC 72 (2.6) 25 (0.9)
ABC FTC/3TC 75 (2.7) 26 (0.9)
DRV TDF FTC/3TC 61 (2.2) 19 (0.7)
ABC FTC/3TC 65 (2.3) 19 (0.7)
* Threshold of the genotypic sensitivity score (GSS) used to consider the strain
as resistant to a given ARV combination. TDF: tenofovir; ABC: abacavir; 3TC:
lamivudine; FTC: emtricitabine; EFV: efavirenz; NVP: nevirapine; LPV: lopinavir;
DRV: darunavir; ATZ: atazanavir.
doi:10.1371/journal.pone.0090710.t003
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only on TDR may also overestimate the impact of circulating
resistances on the clinical effectiveness of first-line PI-containing
regimens. In fact, 93.8% of the patients with TDR to PIs
harboured a single mutation (singleton) in the protease. For classes
including drugs with a high genetic barrier to resistance, such as
PIs [23], the presence of just one mutation should not preclude its
further use for first line regimens. Specific studies on clinically
relevant mutations would be needed for informing this decision.
In a similar way, we have also shown this effect for NRTIs, with
a prevalence of TDR of 3.6%, and a prevalence of clinically
relevant resistance to first line drugs of 2.3%. Again, singletons
were responsible for these differences (55.5% of the patients with
TDR to NRTIs harboured a single mutation). Abacavir and
tenofovir are the two drugs in the NRTI class with the best
resistance profile, being the least affected drugs by single
mutations. In fact most of the discordant cases showing TDR
showed resistance to zidovudine or stavudine, two NRTIs that are
no longer included in Spanish and most international recommen-
dations for first line treatment. In contrast, the NNRTI class,
represented for first line with two low genetic barrier drugs,
showed higher clinically relevant resistance than TDR. This
difference was mainly driven by intermediate resistance calls for
efavirenz and/or nevirapine by a combination of two or more
mutations that are not included in the WHO list, or by the
presence of A98G alone.
Evaluating resistance to specific drugs also allows evaluating the
global therapeutic barrier of a regimen, measuring the global
robustness to resistance of a certain combination rather than
resistance to a certain drug. This may be of extreme importance
for evaluating clinical resistance to first line regimens, establishing
recommendations on how resistance testing should be performed
on newly diagnosed patients, and updating treatment guidelines.
In our study, first line NNRTI containing regimens showed the
lowest therapeutic barrier, as 5.6% to 6.2% of the newly diagnosed
patients from CoRIS, showed any degree of resistance to at least
one of the drugs in the regimen. In contrast, the therapeutic
barrier to first line PI-based regimens was much higher, with
between 2.2% and 2.7% showing any degree of resistance, and
only 0.7% to 0.9% of the patients with two or less active drugs in
the regimen, most of them being fully resistant to emtricitabine or
lamivudine. To our knowledge, this is the first study to estimate the
therapeutic barrier of first line regimens, and our results reinforce
the previously mentioned notion that, in our setting, a reverse
transcriptase-only approach for resistance screening in naı¨ve
patients is a strategy that should be considered. Cost-effectiveness
studies evaluating the different strategies are urgently needed to
better inform drug resistance testing recommendations in our
setting. Some other issues, related to the epidemiological value of
having the protease sequence information, should be considered
and modelled in this analysis.
Our study has several limitations. First, we have studied a subset
of patients included in CoRIS, as a FASTA sequence was only
available for 37.8% of the patients. Restricting to years after 2007,
when the recommendation to screen for resistance in all patients
was made, minimises the possibility of selective testing of patients
with higher probability of resistance. Higher testing in younger
males, MSM of Spanish origin and higher education could reflect
clinicians’ preferences and practices and higher agency of these
patients. However, we cannot rule out that selection bias persists at
a certain scale, resulting in an infra-estimation of resistance rates.
Second, our sequencing data have been obtained through
population sequencing and we have not investigated the presence
of minor populations. As minor variants are known to have a
greater impact on resistance to NNRTIs in naı¨ve patients [24], it is
very unlikely that using this technology our main observations
could have affected resistance to the other classes, in particular for
the PI class. Finally, higher time since HIV infection can limit our
ability to find resistance mutations that were present at infection.
Unfortunately, we did not have information on the date of
infection for most of the patients, although higher CD4 counts,
lower percentage of patients in CDC C stage and a slightly higher
percentage of recent infections in the latter calendar years could
indicate an earlier HIV diagnosis. The fact that we have not found
a decreasing trend in TDR (as of WHO list) indicates that this
bias, if existing, is probably of small magnitude.
In summary, clinically relevant resistance to ART first line
regimens in Spain estimated using the Stanford HIV resistance
database algorithm has been found to be lower than the one we
expected when looking at the WHO surveillance mutations list,
and with a significant trend to a decline through the period 2007–
2011. As PI-based first line regimens have shown the highest
therapeutic barrier and primary resistance to first-line PIs has been
found to be below 1%, we believe that there is a need to question
the recommendation of screening for TDR in the protease gene in
our setting, and that cost-effectiveness studies need to be carried
out to inform evidence-based recommendations.
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